Q32 Bio has stopped a Phase II trial of its former lead renal disease candidate as it focuses on its alopecia areata ...

As we begin 2025, I wanted to take the opportunity to recap on the progress we made in 2024 and key upcoming catalysts including our planned entrance into the multi-billion dollar U.S. market. 2024 ...

Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for BAT2506 in ...

Portable point-of-care blood tests, done by EMS before hospital arrival, need validation but could guide treatment and ...

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without ...

Qlaris Bio has reported positive topline outcomes from two Phase II US trials of QLS 111 in individuals with POAG and OHT.

Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Bio-Rad Laboratories (BIO) one of those stocks right now? A quick glance at ...

South Korea's bioimpedance sensor market thrives on government funding, technological innovation, wearable integration, and ...

South Korea has launched a joint public-private initiative to collect biological data from 1 million individuals, aiming to enhance global competitiveness of the country's bio industry, the finance ...